Needham Reiterates Buy on Insight Molecular, Maintains $9 Price Target
Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. IMDX | 0.00 |
Needham analyst Mike Matson reiterates Insight Molecular (NASDAQ:
IMDX) with a Buy and maintains $9 price target.
